San Francisco Bay Area biotech stories.
Tuesday, July 24, 2012
Cancer drug combo of Nexavar and Tarceva fails late-stage trial
Nexavar, the blockbuster cancer drug from
Onyx Pharmaceuticals Inc.
, failed a late-stage trial that combined the drug with the
Tarceva in patients with advanced liver cancer
Onyx and Bayer said
in a press release Monday
that combining Nexavar and Tarceva tablets in the 720-patient, Phase III trial did not improve overall survival of patients with hepatocellular carcinoma, or HCC. The trial compared the combination therapy to Nexavar alone.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)